Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Tata Memorial Hospital
Alpha Tau Medical LTD.
Alpha Tau Medical LTD.
Alpha Tau Medical LTD.
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
Rigshospitalet, Denmark
Centre Antoine Lacassagne
Centre Antoine Lacassagne
GERCOR - Multidisciplinary Oncology Cooperative Group
University of Michigan
Alpha Tau Medical LTD.
Alpha Tau Medical LTD.
University of Chicago
Oslo University Hospital
Klus Pharma Inc.
Eastern Cooperative Oncology Group
Fox Chase Cancer Center
Rigshospitalet, Denmark
Quadriga Biosciences, Inc.
Tata Memorial Hospital
University of California, San Francisco
Rutgers, The State University of New Jersey
American College of Radiology Imaging Network
University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Radiation Therapy Oncology Group
Hospital de Clinicas de Porto Alegre
Stanford University
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ohio State University Comprehensive Cancer Center
Fox Chase Cancer Center
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fox Chase Cancer Center
GERCOR - Multidisciplinary Oncology Cooperative Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)